Shilpa Medicare Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "Shilpa Medicare and mAbTree Biologics receive FDA Orphan Drug Designation, Advancing Treatment for Rare Blood Cancers".
Press Release Jan 28 2026
Filed with NSE ·
6ix hasn’t read this filing yet.
Shilpa Medicare Limited on 6ix
Earlier from Shilpa Medicare
- Shilpa Pharma Lifesciences Awarded EcoVadis Gold Medal for Outstanding Sustainability Practices
- Shilpa Medicare Announces Positive Phase 3 Results for OERIS™ -- A Novel Once-Weekly Ondansetron Extended-Release Injection for Chemotherapy-Induced Nausea and Vomiting (CINV)
- Shilpa Medicare's NorUDCA Makes History as First Approved NAFLD Therapy Worldwide
- Alveolus Bio Secures Strategic Investment from Shilpa Medicare to Advance Groundbreaking Pulmonary Therapeutics
- Press Release Feb 11 2022
Later from Shilpa Medicare
- Press Release Feb 24 2026
- SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
- Press Release Jun 03 2026
- Shilpa Medicare Limited Press Release Jun 24 2026
- Shilpa Medicare Limited Press Release Jun 30 2026
Follow Shilpa Medicare into a list and get an email when it puts out news.
Follow Shilpa Medicare